[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 68 of about 68
1. Mohan H, Garg S, Punia RP, Dalal A: Combined serous cystadenoma and pancreatic endocrine neoplasm. A case report with a brief review of the literature. JOP; 2007;8(4):453-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined serous cystadenoma and pancreatic endocrine neoplasm. A case report with a brief review of the literature.
  • CONTEXT: The presence of a combined serous cystadenoma and pancreatic endocrine neoplasm is a distinct clinicopathological entity rather than the incidental concurrence of two separate entities.
  • Imaging techniques showed an irregular mass having a mixed solid and cystic consistency, arising from the body of the pancreas and involving the lesser sac.
  • The diagnosis of combined microcystic adenoma and pancreatic endocrine neoplasm was made.
  • CONCLUSION: This case emphasizes the importance of careful gross examination, sampling and reporting of pancreatic tumors.
  • The coexistence of pancreatic endocrine neoplasms with potential malignant behavior may be overshadowed by obvious benign tumors such as a microcystic serous cystadenoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / complications. Cystadenoma, Serous / complications. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625299.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 13
  •  go-up   go-down


2. Malur PR, Suranagi VV, Bannur HB, Kulgod S: Serous microcystic adenoma of the pancreas. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):408-10
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous microcystic adenoma of the pancreas.
  • Serous microcystic adenoma (SMA) is a rare benign neoplasm.
  • It accounts for 1-2% of all exocrine pancreatic tumors.
  • It is usually located in the body and the tail of the pancreas.
  • We present one such rare case of SMA occurring in the head of the pancreas, an infrequent location requiring a Whippel's resection.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679977.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. National Toxicology Program: Toxicology and carcinogenesis studies of 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (CAS No. 31508-00-6) in female harlan Sprague-Dawley rats (gavage studies). Natl Toxicol Program Tech Rep Ser; 2010 Nov;(559):1-174

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the 53-week interim evaluation, three 4,600 g/kg rats had liver cholangiocarcinoma and one had hepatocellular adenoma.
  • At 2 years, there were significant treatment-related increases in the incidences of cholangiocarcinoma and hepatocellular adenoma.
  • At 2 years, there were marginally increased incidences of exocrine pancreatic adenoma or carcinoma in the 460, 1,000, and 4,600 g/kg core study groups.
  • Numerous nonneoplastic effects were seen in other organs including: adrenal cortical atrophy and cytoplasmic vacuolization, pancreatic acinar cell cytoplasmic vacuolization and arterial chronic active inflammation, follicular cell hypertrophy of the thyroid gland, inflammation and respiratory epithelial hyperplasia of the nose, and kidney pigmentation.
  • CONCLUSIONS: Under the conditions of this 2-year gavage study, there was clear evidence of carcinogenic activity of PCB 118 in female Harlan Sprague-Dawley rats based on increased incidences of neoplasms of the liver (cholangiocarcinoma, hepatocholangioma, and hepatocellular adenoma) and cystic keratinizing epithelioma of the lung.
  • Occurrences of squamous cell carcinoma of the uterus and acinar neoplasms of the pancreas may have been related to administration of PCB 118.
  • Administration of PCB 118 caused increased incidences of nonneoplastic lesions in the liver, lung, adrenal cortex, pancreas, thyroid gland, nose, and kidney.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21383778.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 31508-00-6 / 2,3',4,4',5-pentachlorobiphenyl; DFC2HB4I0K / Polychlorinated Biphenyls; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


Advertisement
4. Stern JR, Frankel WL, Ellison EC, Bloomston M: Solid serous microcystic adenoma of the pancreas. World J Surg Oncol; 2007;5:26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid serous microcystic adenoma of the pancreas.
  • BACKGROUND: Cystic neoplasms of the pancreas are less common than solid tumors, and portend a better prognosis.
  • They can be divided into serous and mucinous subtypes, with the former behaving less aggressively and generally considered benign.
  • Of the serous neoplasms, serous microcystic adenoma is the most common.
  • An extremely rare solid variant of serous microcystic adenoma lacking secretory capability has been described.
  • CASE PRESENTATION: We present a case of a 62 year-old man with a history of abdominal pain, who on CT scan was found to have a solid mass at the junction of the head and body of the pancreas.
  • The patient was offered resection for diagnosis and treatment, and subsequently underwent distal pancreatectomy and splenectomy.
  • Based on gross pathology, histology and immunohistochemistry, the mass was determined to be a solid serous microcystic adenoma.
  • CONCLUSION: Solid serous microcystic adenoma shows similar histologic and immunohistologic features to its classic cystic counterpart, but lacks any secretory functionality.
  • It appears to behave in a benign manner, and as such, surgical resection is curative for patients with this tumor.
  • Furthermore, until more cases of solid SMA are identified to further elucidate its natural history and improve the reliability of preoperative diagnosis, surgical resection of this solid pancreatic tumor should be considered standard therapy in order to exclude malignancy.
  • [MeSH-major] Adenoma / pathology. Adenoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Laparoscopy / methods. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Rare Diseases. Risk Assessment. Splenectomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2002 Apr;52(4):307-12 [12031087.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):339-46 [15104296.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Cancer. 1992 May 15;69(10):2449-53 [1568167.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1237-42 [17001153.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1963-6 [9772066.001]
  • [Cites] Pathol Int. 2005 Jul;55(7):436-9 [15982220.001]
  • [Cites] Pancreas. 2006 Jul;33(1):96-9 [16804417.001]
  • [Cites] Pancreatology. 2006;6(3):248-53 [16543776.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1553-9 [16773248.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1401-5 [8898845.001]
  • (PMID = 17338818.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1821026
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


5. Dietrich CF, Braden B, Hocke M, Ott M, Ignee A: Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound. J Cancer Res Clin Oncol; 2008 Jun;134(6):635-43
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound.
  • The role of CEUS in pancreatic disease is less obvious.
  • We prospectively evaluated CEUS for characterization of undetermined solid pancreatic lesions (gold standard histology).
  • PATIENTS AND METHODS: A total of 112 solitary undetermined pancreatic masses (70 ductal adenocarcinoma and 42 neoplastic nodules of other origin) were prospectively examined in patients without metastatic disease using transabdominal ultrasound.
  • Tumour enhancing features were analyzed in comparison to the surrounding pancreatic parenchyma in patients with adequate visualisation.
  • CONCLUSION: CEUS allows differential diagnosis of ductal adenocarcinoma and non-ductal adenocarcinoma (mainly neuroendocrine tumours and (microcystic) serous pancreatic adenoma) in the most of cases.
  • [MeSH-major] Abdomen / diagnostic imaging. Pancreatic Neoplasms / diagnostic imaging
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adult. Aged. Aged, 80 and over. Contrast Media. Diagnosis, Differential. Endosonography. Female. Humans. Image Enhancement. Lymphoma / diagnostic imaging. Male. Middle Aged. Neuroendocrine Tumors / diagnostic imaging. Prospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Cancer Res Clin Oncol. 2008 Jun;134(6):723
  • [Cites] Eur J Radiol. 2001 May;38(2):94-104 [11335091.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Jul;11(7):747-53 [10445795.001]
  • [Cites] J Ultrasound Med. 2004 Dec;23 (12 ):1557-68 [15557299.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12 (2):246-50 [16482625.001]
  • [Cites] Radiology. 1974 Aug;112(2):275-82 [4835020.001]
  • [Cites] Pancreas. 2003 Jan;26(1):76-81 [12499921.001]
  • [Cites] J Ultrasound Med. 2005 Jun;24(6):849-54 [15914689.001]
  • [Cites] World J Gastroenterol. 2006 Jul 14;12 (26):4181-4 [16830370.001]
  • [Cites] J Am Coll Surg. 1994 Dec;179(6):747-57 [7952490.001]
  • [Cites] Pancreas. 2004 Apr;28(3):335-43 [15084983.001]
  • [Cites] Semin Diagn Pathol. 2004 Nov;21(4):260-7 [16273945.001]
  • [Cites] AJR Am J Roentgenol. 1997 Nov;169(5):1263-7 [9353439.001]
  • [Cites] Hepatology. 1997 Aug;26(2):467-72 [9252160.001]
  • [Cites] Cancer Imaging. 2006 Dec 20;6:199-203 [17208676.001]
  • [Cites] Am J Gastroenterol. 1998 Apr;93(4):632-5 [9576461.001]
  • [Cites] AJR Am J Roentgenol. 2002 Nov;179(5):1273-9 [12388513.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1699-705 [16586537.001]
  • [Cites] Cancer. 2005 Mar 1;103(5):1026-35 [15672386.001]
  • [Cites] Radiology. 1999 Jul;212(1):213-8 [10405744.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):144-52 [15654794.001]
  • [Cites] Nihon Rinsho. 1998 Apr;56(4):1024-9 [9577628.001]
  • [Cites] Gut. 2004 Mar;53(3):401-5 [14960524.001]
  • [Cites] Radiology. 2006 Nov;241(2):441-8 [16982815.001]
  • [Cites] Gut. 2005 Jul;54(7):1047 [15951559.001]
  • [Cites] JOP. 2006 Nov 10;7(6):584-92 [17095837.001]
  • [Cites] Ultraschall Med. 2005 Aug;26(4):277-84 [16123921.001]
  • [Cites] J Ultrasound Med. 2002 Apr;21(4):409-16; quiz 417 [11934098.001]
  • [Cites] J Gastroenterol. 2005 Jun;40(6):631-40 [16007398.001]
  • [Cites] J Ultrasound Med. 2003 Aug;22(8):789-95 [12901406.001]
  • [Cites] J Gastroenterol. 2005 Jun;40(6):666-8 [16007407.001]
  • [Cites] Z Gastroenterol. 2004 Apr;42(4):317-21 [15095122.001]
  • [Cites] J Gastroenterol. 2005 May;40(5):518-25 [15942718.001]
  • [Cites] AJR Am J Roentgenol. 2002 May;178(5):1133-7 [11959716.001]
  • [Cites] Gut. 2004 Jun;53(6):854-9 [15138213.001]
  • [Cites] J Ultrasound Med. 2004 Aug;23 (8):1125-9 [15284474.001]
  • [Cites] Pancreatology. 2005;5(4-5):398-402 [15985763.001]
  • (PMID = 17952469.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


6. Sanada Y, Yoshida K: A case of benign intraductal papillary mucinous neoplasm of the pancreas containing two major subtypes. J Gastrointestin Liver Dis; 2008 Dec;17(4):457-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of benign intraductal papillary mucinous neoplasm of the pancreas containing two major subtypes.
  • Here we report a case of benign intraductal papillary-mucinous neoplasm (IPMN) of the pancreas containing two major subtypes.
  • Histopathologic examinations revealed that IPMN was composed of gastric-type adenoma and intestinal-type borderline lesion.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Mixed Tumor, Malignant / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastrointestin Liver Dis. 2009 Jun;18(2):251-2 [19565062.001]
  • (PMID = 19104710.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Mucin-2
  •  go-up   go-down


7. Limi L, Liew NC, Badrul RH, Faisal MJ, Daniel YP: Duodenal intussusception of Brunner's gland adenoma mimicking a pancreatic tumour. Med J Malaysia; 2010 Dec;65(4):311-2
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal intussusception of Brunner's gland adenoma mimicking a pancreatic tumour.
  • Brunner's gland adenoma is a rare benign tumour of the duodenum.
  • We report a 40-year old lady, presenting with upper gastrointestinal bleeding and was found to have prolapsed and intussuscepted Brunner's gland adenoma of the duodenum, which mimicked the appearance of a tumour in the head of pancreas.
  • [MeSH-major] Adenoma / diagnosis. Brunner Glands / pathology. Duodenal Neoplasms / diagnosis. Intussusception / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21901954.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


8. Choi H, Kim S, Moon JH, Lee YH, Rhee Y, Kang ES, Ahn CW, Cha BS, Lee EJ, Kim KR, Lee HC, Jeong SY, Kim HJ, Lim SK: Multiple endocrine neoplasia type 1 with multiple leiomyomas linked to a novel mutation in the MEN1 gene. Yonsei Med J; 2008 Aug 30;49(4):655-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEN1 is characterized by the presence of functioning and nonfunctioning tumors or hyperplasia of the pituitary gland, parathyroid glands, and pancreatic islet cells.
  • Endoscopic ultrasonography demonstrated esophageal leiomyoma and pancreatic islet cell tumor.
  • This is the first case of MEN1 accompanied with multiple leiomyomas, parathyroid adenoma, pituitary adenoma, pancreatic tumor, and adrenal tumor.


9. Cui Y, Tian M, Zong M, Teng M, Chen Y, Lu J, Jiang J, Liu X, Han J: Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma. Pancreatology; 2009;9(1-2):89-98
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma.
  • BACKGROUND: Dual expression of potential biomarkers in both benign and malignant pancreatic tumors was a major obstacle in the development of diagnostic biomarkers of early pancreatic cancer.
  • METHODS: To better understand the limitations of potential protein biomarkers in pancreatic cancer, we employed two-dimensional difference gel electrophoresis technology and tandem mass spectrometry to study protein expression profiles in pancreatic cancer tissues, benign pancreatic adenoma and normal adjacent pancreas.
  • RESULTS: 21 spots were overexpressed and 24 spots were downexpressed in pancreatic cancer compared with benign and normal adjacent tissues.
  • Our study demonstrated that three candidate pancreatic ductal adenocarcinoma biomarkers identified in previous studies, fructose-bisphosphate aldolase A, alpha-smooth muscle actin and vimentin, were also overexpressed in pancreatic cystadenoma, which might lower their further utility as biomarkers for pancreatic cancer.
  • Aflatoxin B(1) aldehyde reductase (AKR7A2) was confirmed to be only highly expressed in pancreatic cancer, not in normal adjacent pancreas and benign tumors.
  • CONCLUSIONS: The protein profile pattern of pancreatic cystadenoma was more similar to normal adjacent pancreas than pancreatic cancer.
  • We identified panels of the upregulated proteins in pancreatic cancer, which have not been reported in prior proteomic studies.
  • AKR7A2 may be a novel potential biomarker for pancreatic cancer.
  • [MeSH-major] Aldehyde Reductase / biosynthesis. Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / metabolism. Cystadenoma / metabolism. Pancreas / metabolism. Pancreatic Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077459.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chaperonin 60; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / PARK7 protein, human; 0 / Vimentin; 117896-08-9 / nucleophosmin; EC 1.1.1.- / aflatoxin B1 aldehyde reductase; EC 1.1.1.21 / Aldehyde Reductase; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase
  •  go-up   go-down


10. Gómez-Pérez FJ, Cuevas-Ramos D, Valdés PA, Aguilar-Salinas CA, Mehta R, Rull JA: Beta-cell adenomas without hyperinsulinemia with use of highly specific insulin radioimmunoassays: case report and review of literature. Endocr Pract; 2010 Jul-Aug;16(4):660-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report a case of a proinsulin-secreting islet cell adenoma in which the diagnosis was obscured by an ultraspecific insulin assay.
  • Magnetic resonance imaging and endoscopic ultrasonography confirmed the presence of a 2.5-cm tumor in the head of the pancreas.
  • CONCLUSION: The diagnosis of a hypoglycemia-producing pancreatic adenoma can be missed when an ultraspecific insulin assay is used.
  • The direct measurement of proinsulin established the diagnosis in this case.
  • [MeSH-major] Insulinoma / blood. Insulinoma / diagnosis. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / diagnosis. Proinsulin / blood
  • [MeSH-minor] Diagnosis, Differential. Endosonography. Female. Humans. Hypoglycemia / blood. Insulin / blood. Magnetic Resonance Imaging. Middle Aged. Radioimmunoassay

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439243.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin; 9035-68-1 / Proinsulin
  •  go-up   go-down


11. Stamatakos M, Safioleas C, Tsaknaki S, Safioleas P, Iannescu R, Safioleas M: Insulinoma: a rare neuroendocrine pancreatic tumor. Chirurgia (Bucur); 2009 Nov-Dec;104(6):669-73
MedlinePlus Health Information. consumer health - Rare Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulinoma: a rare neuroendocrine pancreatic tumor.
  • Insulinomas are functional endocrine tumors originating from the pancreatic b-cells.
  • In 1902 Nicholls described the first adenoma of pancreatic islets, while the first insulinoma was described in 1927 in Mayo Clinic, which was dissected two years later in 1929 in Toronto.
  • [MeSH-major] Insulinoma / diagnosis. Neuroendocrine Tumors / diagnosis. Pancreatic Neoplasms / diagnosis. Rare Diseases
  • [MeSH-minor] Diagnosis, Differential. History, 20th Century. Humans. Hypoglycemia / etiology. Pancreatectomy. Prevalence. Romania / epidemiology. Treatment Outcome


12. Hayasaka K, Nihashi T, Matsuura T, Itoh K, Tokuda H: Usefulness of F-18 FDG-PET in detection of multiple endocrine tumors with duodenal carcinoid. Comput Med Imaging Graph; 2007 Apr;31(3):191-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a 76-year-old woman in whom hypercalcemia had been followed, whole body fluorodeoxyglucose positron emission tomography (FDG-PET) scan detected hypermetabolic areas in the left lower region of the thyroid gland, pancreas tail, and duodenum.
  • CT, MR, biopsy, and surgery were performed and parathyroid adenoma, pancreatic gastrinoma, and duodenal carcinoid were diagnosed.
  • Fluorine-18 (F-18) FDG-PET may be useful for diagnosis of multiple endocrine tumors with duodenal carcinoid.
  • [MeSH-major] Duodenal Neoplasms / diagnosis. Endocrine System / radiography. Positron-Emission Tomography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383156.001).
  • [ISSN] 0895-6111
  • [Journal-full-title] Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  • [ISO-abbreviation] Comput Med Imaging Graph
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Machado MC, Machado MA: Solid serous adenoma of the pancreas: an uncommon but important entity. Eur J Surg Oncol; 2008 Jul;34(7):730-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid serous adenoma of the pancreas: an uncommon but important entity.
  • Serous cystic neoplasms of the pancreas have currently five recognized subtypes: serous microcystic adenoma, serous oligocystic ill-demarcated adenoma, solid serous adenoma, von Hippel-Lindau-associated cystic neoplasm, and serous cystadenocarcinoma.
  • Solid serous adenoma of the pancreas is by far the rarest subtype with only nine cases published thus far.
  • In this review, we will discuss clinical features, imaging characteristics and histopathological findings, considering in particular (1) difficulties in preoperative diagnosis; and (2) relevant immunohistochemical analysis.
  • After analyzing the literature, including one case from our Department, we can conclude that there is enough evidence to support that solid serous adenomas of the pancreas is a solid variant of serous cystadenomas.
  • Preoperative diagnosis is difficult to establish but magnetic resonance cholangiopancreatography may be useful.
  • Given benign nature of this solid variant conservative surgery is recommended.
  • It is definitively a rare entity but oncologic surgeons should be aware of this neoplasm in order to make a correct preoperative diagnosis that will ultimately result in more conservative surgeries.
  • [MeSH-major] Cystadenoma, Serous / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440191.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 12
  •  go-up   go-down


14. Kitagawa H, Okabayashi T, Nishimori I, Kobayashi M, Sugimoto T, Akimori T, Kohsaki T, Miyaji E, Onishi S, Araki K: Rapid growth of mucinous cystic adenoma of the pancreas following pregnancy. Int J Gastrointest Cancer; 2006;37(1):45-8
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid growth of mucinous cystic adenoma of the pancreas following pregnancy.
  • Abdominal computed tomography and upper abdominal ultrasonography revealed a large cystic mass in the body of the pancreas.
  • Endoscopic retrograde pancreatography showed no connection between the main pancreatic duct and the cystic lesion.
  • Pathological examination of the tumor revealed mucin-producing columnar epithelial cells lining the cystic wall with ovarian-type stromal tissue and no findings indicative of malignancy, giving a diagnosis of mucinous cystic adenoma of the pancreas.
  • Postpartum rapid growth of a benign mucinous cystic neoplasm might be linked to the production of female sex hormones during lactation.
  • [MeSH-major] Adenoma / pathology. Cystadenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 1999 Feb;65(2):105-11 [9926740.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] World J Surg Oncol. 2005 Sep 07;3:59 [16146567.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):282-7 [15780564.001]
  • [Cites] Virchows Arch. 2000 May;436(5):473-80 [10881741.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):203-5 [15221374.001]
  • (PMID = 17290080.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Colović R, Grubor N, Micev M, Ranković V, Matić S, Latincić S: [Serous microcystic adenoma of the head of the pancreas causing an obstructive jaundice]. Vojnosanit Pregl; 2008 Nov;65(11):839-42
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serous microcystic adenoma of the head of the pancreas causing an obstructive jaundice].
  • BACKGROUND: Serous microcystic adenoma is a rare benign tumor of the exocrine pancreas originating from the ductal system and composed of a large number of small cysts covered by cuboid cells, filled with clear serous fluid and separated with fibrocolagenous stroma.
  • Most frequently it appears in women in 7th and 8th decades, in the distal pancreas.
  • In 2/3 of patients symptoms are uncharacteristic and in 1/3 they are absent When localised within the head of the pancreas it rarely causes an obstructive jaundice.
  • At surgery we revealed a rather large policystic mass of the head of the pancreas causing not only obstructive jaundice but also a venous stasis by compression and dislocation of the portomesenteric vein.
  • Histology confirmed serous microcystic adenoma of the pancreas.
  • CONCLUSION: Although very rare, serous microcystic adenoma might appear within the head of the pancreas and has to be taken into consideration in differential diagnosis of cystic lesions of the head of the pancreas.
  • [MeSH-major] Cystadenoma, Serous / complications. Jaundice, Obstructive / etiology. Pancreatic Neoplasms / complications
  • [MeSH-minor] Female. Humans. Middle Aged. Pancreas, Exocrine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069716.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


16. Nobili C, Franciosi C, Degrate L, Caprotti R, Romano F, Perego E, Trezzi R, Leone BE, Uggeri F: A case of pancreatic heterotopy of duodenal wall, intraductal papillary mucinous tumor and intraepithelial neoplasm of pancreas, papillary carcinoma of kidney in a single patient. Tumori; 2006 Sep-Oct;92(5):455-8
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pancreatic heterotopy of duodenal wall, intraductal papillary mucinous tumor and intraepithelial neoplasm of pancreas, papillary carcinoma of kidney in a single patient.
  • We report a case of the contemporaneous presence of two histologically different pancreatic neoplasms, one renal cancer and one embryogenic duodenal anomaly in a single patient.
  • Computed tomography confirmed the renal lesion, but also a heterogeneous mass within the pancreatic head appeared without bile ducts dilatation.
  • Abdominal magnetic resonance revealed a multiloculated cystic component of the pancreatic mass.
  • A second CT scan confirmed the renal and biliary findings, but it revealed a modest enlargement of the pancreatic asymptomatic mass.
  • Histopathologic analysis of the surgical specimen revealed mild differentiated papillary renal carcinoma, intraductal papillary mucinous adenoma of the pancreatic head, foci of intraepithelial pancreatic neoplasm and pancreatic heterotopy of duodenal muscular and submucosal layers.
  • [MeSH-major] Carcinoma, Pancreatic Ductal. Carcinoma, Papillary. Choristoma. Cystadenocarcinoma, Mucinous. Duodenal Diseases. Kidney Neoplasms. Neoplasms, Multiple Primary. Pancreas. Pancreatic Neoplasms
  • [MeSH-minor] Aged. Carcinoma, Renal Cell / diagnosis. Humans. Magnetic Resonance Imaging. Male. Nephrectomy / methods. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168444.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Bhople KS, Joshi AR, Patil SP, Tembhare PR: Microcystic adenoma of pancreas: a case report. Indian J Pathol Microbiol; 2007 Apr;50(2):334-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adenoma of pancreas: a case report.
  • Microcystic adenomas of the pancreas are rare benign neoplasms that occur most frequently in elderly females.
  • In this case report, we present a cystic neoplasm of pancreas in a 65-year-old lady who clinically presented with discomfort in the abdomen and hyperglycaemia.
  • Histopathological examination of surgical specimen confirmed the diagnosis of "Microcystic Adenoma ofPancreas".
  • Despite of the rarity, microcystic adenoma should kept in the mind as the differential diagnosis of cystic lesions of pancreas.
  • [MeSH-major] Adenoma / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Pancreatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883062.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


18. Nagaike K, Chijiiwa K, Hiyoshi M, Ohuchida J, Kataoka H: Main-duct intraductal papillary mucinous adenoma of the pancreas with a large mural nodule. Int J Clin Oncol; 2007 Oct;12(5):388-91
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Main-duct intraductal papillary mucinous adenoma of the pancreas with a large mural nodule.
  • Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized entity representing a spectrum of benign and malignant neoplasms of the pancreas.
  • Preoperative distinction between benign and malignant IPMNs remains difficult.
  • Reported predictive factors for malignancy are size of the main pancreatic duct, cystic neoplasm, and mural nodule.
  • We report herein the case of a 50-year-old woman in whom a large mural nodule (30 mm) in the dilated main pancreatic duct (16 mm in diameter) was detected by ultrasonography, computed tomography, and endoscopic retrograde cholangiopancreatography.
  • Because the large mural nodule and dilatation of the main pancreatic duct were also detected by endoscopic ultrasonography (EUS) and intraductal ultrasonography (IDUS), the main-duct IPMN was considered to have malignant potential.
  • The final diagnosis was intraductal papillary mucinous adenoma of the pancreas.
  • The size of the mural nodule and the final diagnosis in this case suggest that the introduction of a novel molecular-biological approach might be necessary for the precise preoperative diagnosis of main-duct IPMN and adequate surgical treatment.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Cystadenoma, Mucinous / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):164-71 [9717782.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Eur J Surg. 1999 Mar;165(3):223-9 [10231655.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Am Surg. 2001 May;67(5):400-6 [11379635.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • (PMID = 17929124.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Yan JQ, Peng CH, Yang WP, Ding JZ, Zhou GW, Ma D, Li HW: Surgical management of benign duodenal tumours. ANZ J Surg; 2010 Jul-Aug;80(7-8):526-30
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of benign duodenal tumours.
  • BACKGROUND: While benign duodenal tumours are rare compared with malignant tumours, they comprise a wide variety of pathologies.
  • Despite their diagnostic challenge, the optimal management of benign duodenal tumours remains undefined.
  • We aimed to review the diagnosis and surgical treatment of benign duodenal tumours.
  • METHODS: Records of all patients with post-operative pathological diagnosis of benign duodenal tumour were retrieved.
  • The post-operative pathology results indicated 5 cases of adenoma, 2 cases of tubular adenoma, 2 cases of villous adenoma, 2 cases of tubulovillous adenoma, 2 cases of hamartoma and 1 case each of hamartomatous polyp, Brunner's adenoma, adenomyoma, fibromatosis and ectopic pancreas.
  • CONCLUSION: The presentation of benign duodenal tumours is non-specific, with upper abdominal discomfort and upper gastrointestinal bleeding as common symptoms.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Anastomosis, Surgical / methods. Biopsy, Needle. Cholangiopancreatography, Endoscopic Retrograde / methods. Cohort Studies. Colectomy / methods. Duodenoscopy / methods. Female. Follow-Up Studies. Hamartoma / diagnosis. Hamartoma / pathology. Hamartoma / surgery. Humans. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Tomography, X-Ray Computed / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ANZ J Surg. 2011 Apr;81(4):300-1 [21418483.001]
  • (PMID = 20795967.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


20. Gomez-Godinez V, Wakida NM, Dvornikov AS, Yokomori K, Berns MW: Recruitment of DNA damage recognition and repair pathway proteins following near-IR femtosecond laser irradiation of cells. J Biomed Opt; 2007 Mar-Apr;12(2):020505
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 800-nm 200-fs laser is used to produce DNA damage in rat kangaroo (PtK1) and human cystic fibrosis pancreatic adenoma carcinoma (CFPAC-1) cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17477704.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 69337; United States / NCRR NIH HHS / RR / RR 14892
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 9007-49-2 / DNA
  •  go-up   go-down


21. Fitzhugh VA, Mirani N, Aisner S, Koneru B, Das K: Preoperative fine needle aspiration cytology diagnosis of microcystic adenoma of the pancreas: fact or fiction? A report of 2 cases. Acta Cytol; 2008 Mar-Apr;52(2):240-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative fine needle aspiration cytology diagnosis of microcystic adenoma of the pancreas: fact or fiction? A report of 2 cases.
  • BACKGROUND: Microcystic adenoma is an uncommon benign neoplasm involving the pancreas that usually affects older populations.
  • CASES: We report 2 cases of microcystic adenoma of the pancreas in which an accurate diagnosis could not be rendered on cytology material alone.
  • CONCLUSION: A preoperative diagnosis can be helpful in guiding the care of the patient, thereby increasing the importance of a diagnosis to distinguish between a benign vs. malignant process.
  • These case reports demonstrate the difficulty of obtaining diagnostic cells in microcystic adenoma, highlight the use of FNA to increase cellular yield and emphasize the importance of correlating radiologic findings with aspiration of abundant watery fluid from cystic pancreatic masses to make a definitive diagnosis.
  • [MeSH-major] Adenoma / pathology. Biopsy, Fine-Needle. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500004.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Tomimaru Y, Takeda Y, Tatsumi M, Kim T, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Kitagawa T, Nagano H, Umeshita K, Wakasa K, Doki Y, Mori M: Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep; 2010 Sep;24(3):613-20
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
  • Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas presents in various histopathological stages from benign to malignant lesions.
  • The differentiation between benign and malignant IPMN is important in order to determine the treatment of the patients.
  • The aim of this study was to assess the utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in pre-operative differentiation of benign and malignant IPMN of the pancreas.
  • The maximum standardized uptake value (SUVmax) was determined on FDG-PET, and differentiation of benign from malignant IPMN was tested using various SUVmax cut-off levels and various parameters derived from the CT.
  • SUVmax was found to be significantly higher in malignant IPMNs (4.7+/-3.0) than that in benign IPMNs (1.8+/-0.3, P=0.0011).
  • SUVmax values correlated with the histopathological types of IPMN (adenoma/borderline lesion/carcinoma in situ/invasive carcinoma) (Spearman rank correlation 0.865, P<0.0001).
  • The combination of mural nodule, detected on CT, and SUVmax of 2.5 offered the best diagnosis of malignant IPMN.
  • These results suggest that FDG-PET is useful for differentiation of malignant IPMN of the pancreas, and that it should be performed in combination with other conventional imaging modalities.
  • [MeSH-major] Adenoma / radionuclide imaging. Carcinoma in Situ / radionuclide imaging. Carcinoma, Pancreatic Ductal / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasms, Cystic, Mucinous, and Serous / radionuclide imaging. Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Japan. Male. Middle Aged. Pancreatectomy. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664965.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Mlika M, Farah F, Jarboui S, Abdessalem M, Zaouche A, Jilani SB, Zermani R: A benign cystic mass of the pancreas mimicking a malignant lesion. Pathologica; 2009 Dec;101(6):261-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A benign cystic mass of the pancreas mimicking a malignant lesion.
  • Herein, we highlight the diagnostic challenges of cystic pancreatic tumours, and report a case of chronic pancreatitis caused by a cystic tumour, which consisted in a canal dilatation--and not a pseudocyst.
  • The case thus demonstrates a rare association between a cystic form of chronic pancreatitis and adrenal adenoma.
  • Imaging findings (ultrasound, CT-scan, MRI) showed a 3-cm cystic lesion of the tail of the pancreas associated with a 3-cm adrenal mass.
  • Pathological findings consisted in fibrotic chronic pancreatitis with canal dilatation and an adrenal adenoma.
  • Pancreatic cystic lesions are rare tumours.
  • Final diagnosis must be based on pathological features.
  • [MeSH-major] Pancreatic Cyst / pathology. Pancreatic Neoplasms / pathology. Pancreatitis, Chronic / pathology
  • [MeSH-minor] Adenoma / complications. Adenoma / pathology. Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / pathology. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387716.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Ohno E, Hirooka Y, Itoh A, Ishigami M, Katano Y, Ohmiya N, Niwa Y, Goto H: Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules. Ann Surg; 2009 Apr;249(4):628-34
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules.
  • BACKGROUND AND AIM: Intraductal papillary mucinous neoplasms (IPMNs)have a wide pathologic spectrum and it is difficult to differentiate malignant from benign tumors.
  • RESULTS: Forty-two, 26, 16, and 3 were pathologically diagnosed as adenoma,noninvasive carcinoma, invasive IPMNs, and coexistent invasive ductal cancer, respectively.
  • The diagnosis of IPMNs with types III or IV mural nodule as malignant resulted in a sensitivity of 60%, specificity of 92.9%, and accuracy of 75.9%.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / ultrasonography. Endosonography / methods. Neoplasm Invasiveness / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / ultrasonography. Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Fine-Needle. Cohort Studies. Confidence Intervals. Contrast Media. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Logistic Models. Male. Mucous Membrane / pathology. Mucous Membrane / ultrasonography. Multivariate Analysis. Neoplasm Staging. Odds Ratio. Probability. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300203.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


25. Petersen M, Evert M, Schneider-Stock R, Pross M, Rüschoff J, Roessner A, Lippert H, Meyer F: Serous oligocystic adenoma (SOIA) of the pancreas--first reported case of a genetically fixed association in a patient with hereditary non-polyposis colorectal cancer (HNPCC). Pathol Res Pract; 2009;205(11):801-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous oligocystic adenoma (SOIA) of the pancreas--first reported case of a genetically fixed association in a patient with hereditary non-polyposis colorectal cancer (HNPCC).
  • Cystic tumor lesions of the pancreas are relatively uncommon.
  • A promoting aspect is the extended indication profile in pancreatic surgery, in particular, because of lower perioperative morbidity and mortality.
  • One of these classified cystic neoplasms of the pancreas is serous oligocystic adenoma (SOIA), a rare and benign tumor lesion.
  • We report on a 41-year-old man with a cystic lesion within the pancreatic head.
  • Both tumor tissue specimens had been characterized for a high level of microsatellite instability (MSI) and loss of hMLH1, as well as for a corresponding germ line mutation in hMLH1 gene, leading to the diagnosis of hereditary non-polyposis associated colon cancer (HNPCC).
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Cystadenoma / genetics. Pancreatic Neoplasms / genetics


26. Adsay NV: Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg; 2008 Mar;12(3):401-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic neoplasia of the pancreas: pathology and biology.
  • In contrast with solid tumors, most of which are invasive ductal adenocarcinoma with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • While many are innocuous adenomas--in particular, those that are small and less complex, and in the case of IPMN, those that are branch-duct type are more commonly benign, some harbor or progress into in situ or invasive carcinomas.
  • For this reason, pancreatic cysts with mucinous differentiation ought to be evaluated carefully, preferably by experts familiar with subtle evidences of malignancy in these tumors.
  • The presence of ovarian-type stroma has now almost become a requirement for the diagnosis of MCN, and when defined as such, MCN is seen almost exclusively in women of perimenopausal age group as thick-walled multilocular cystic mass in the tail of the pancreas in contrast with IPMN which afflicts an elder population, both genders in almost equal numbers, and occur predominantly in the head of the organ.
  • SPT holds a distinctive place among pancreatic neoplasia because of its highly peculiar characteristics, undetermined cell lineage, occurrence almost exclusively in young females, association with beta-catenin pathway, and also by being a very low-grade curable malignancy.
  • In conclusion, cystic lesions in the pancreas constitute a biologically and pathologically diverse category most (but not all) of which are either benign or treatable diseases; however, a substantial subset, especially mucinous ones, has malignant potential that requires careful analysis.
  • [MeSH-major] Adenoma / pathology. Carcinoma in Situ / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Cystadenoma / pathology. Cystadenoma, Serous / pathology. Dilatation, Pathologic. Humans. Necrosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):81-8 [10721809.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):56-65 [10721807.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S71-93 [17486054.001]
  • [Cites] World J Surg. 2003 Mar;27(3):319-23 [12607059.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • (PMID = 17957438.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


27. Yamaguchi K, Nakamura M, Shirahane K, Kawamoto M, Konomi H, Ohta M, Tanaka M: Pancreatic juice cytology in IPMN of the pancreas. Pancreatology; 2005;5(4-5):416-21; discussion 421
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic juice cytology in IPMN of the pancreas.
  • BACKGROUND: Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas is a disease ranging from adenoma to borderline (with moderate dysplasia) and further to carcinoma (noninvasive and invasive) and surgical strategy is different by the grades of dysplasia.
  • METHODS: Preoperative pancreatic juice cytology in IPMN was reviewed in 71 patients with IPMN who underwent surgical resection.
  • RESULTS: The IPMN was adenoma in 48 patients, borderline in 13 and carcinoma (invasive) in 10.
  • The sensitivity of pancreatic juice cytology in malignant IPMN was 40% (4/10).
  • In 4 patients with the 48 IPM adenomas, diagnosis of pancreatic juice cytology was class IV or V.
  • Sensitivity of pancreatic juice cytology was higher in IPMN of the main duct type with mucin hypersecretion and with mural nodules.
  • CONCLUSIONS: These findings suggest that pancreatic juice cytology in IPMN is useful especially in the main duct type with mucin hypersecretion and mural nodules.
  • When the diagnosis of pancreatic juice cytology is malignant in otherwise benign-looking IPMNs, coexistence of pancreatic carcinoma should be suspected.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Cytodiagnosis / methods. Pancreatic Juice / cytology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / classification. Adenoma / diagnosis. Aged. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15985766.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


28. Gourgiotis S, Ridolfini MP, Germanos S: Intraductal papillary mucinous neoplasms of the pancreas. Eur J Surg Oncol; 2007 Aug;33(6):678-84
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas.
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasms (IPMNs) are neoplasms of the pancreatic duct epithelium characterized by intraductal papillary growth and thick mucin secretion.
  • Quantities of mucin fill the main and/or branches of pancreatic ducts and cause ductal dilatation.
  • This review encompasses IPMNs, including symptoms, diagnosis, management, and prognosis.
  • Most branch type IPMNs are benign, while the other two types are frequently malignant.
  • Presence of a large branch type IPMN and marked dilatation of the main duct indicate the existence of adenoma at least.
  • CONCLUSIONS: Prognosis is excellent after complete resection of benign and non-invasive malignant IPMNs.
  • The extent of pancreatic resection and the intraoperative management of resection margins remain controversial.
  • Total pancreatectomy should be reserved for patients with resectable but extensive IPMNs involving the whole pancreas; its benefits, however, must be balanced against operative and postoperative risks.
  • [MeSH-major] Pancreatic Ducts / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Dilatation, Pathologic / pathology. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207960.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 76
  •  go-up   go-down


29. Kawamoto S, Horton KM, Lawler LP, Hruban RH, Fishman EK: Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT? Radiographics; 2005 Nov-Dec;25(6):1451-68; discussion 1468-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT?
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a distinct clinicopathologic entity that is being recognized with increasing frequency.
  • The spectrum of appearances of IPMN, which includes adenoma, borderline lesion, and lesions with associated carcinoma in situ or invasive carcinoma, was studied with 16-section multidetector computed tomography (CT) and histologic correlation.
  • Features predictive of invasive carcinoma in IPMN at CT and other imaging studies include involvement of the main pancreatic duct, marked dilatation of the main pancreatic duct, diffuse or multifocal involvement, the presence of a large mural nodule or solid mass, large size of the mass, and obstruction of the common bile duct.
  • [MeSH-major] Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Papillary / radiography. Neoplasms, Multiple Primary / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005.
  • (PMID = 16284127.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


30. Konishi M, Kinoshita T, Nakagohri T, Takahashi S, Gotohda N, Ryu M: Pancreas-sparing duodenectomy for duodenal neoplasms including malignancies. Hepatogastroenterology; 2007 Apr-May;54(75):753-7
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreas-sparing duodenectomy for duodenal neoplasms including malignancies.
  • BACKGROUND/AIMS: Pancreas-sparing duodenectomy (PSD) represents an attractive operation for benign or premalignant duodenal disease.
  • METHODOLOGY: The present study investigated 16 patients who underwent PSD for duodenal neoplasms including adenoma, cancer, carcinoid and non-epithelial tumor.
  • This study classified PSD into 4 types based on the resected portion of the duodenum, as used in gastrectomy (total, subtotal, distal, and proximal) and we experienced pancreas-sparing proximal duodenectomy and pancreas-sparing distal duodenectomy.
  • RESULTS: Pancreatic fistula or anastomotic leak occurred in 2 patients, and were closed with nonoperative management.
  • The remaining 10 patients are well, with no symptoms related to the hepatobiliary and pancreatic systems.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / diagnosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591055.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


31. Miura T, Igarashi Y, Okano N, Miki K, Okubo Y: Endoscopic diagnosis of intraductal papillary-mucinous neoplasm of the pancreas by means of peroral pancreatoscopy using a small-diameter videoscope and narrow-band imaging. Dig Endosc; 2010 Apr;22(2):119-23
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic diagnosis of intraductal papillary-mucinous neoplasm of the pancreas by means of peroral pancreatoscopy using a small-diameter videoscope and narrow-band imaging.
  • Therefore, it is important to determine whether an IPMN is benign or malignant.
  • We carried out the differential diagnosis of benign lesion to malignant lesion.
  • METHODS: Between April 2003 and May 2009, PPS using a small-diameter videoscope by means of NBI was carried out on 21 hospitalized patients with IPMN (10 cases of adenocarcinoma, 11 cases of adenoma or hyperplasia; 14 males and seven females, with a mean age of 69.4 years).
  • RESULTS: Fifteen focal lesions of the 16 cases in the head of the pancreas (93.7%) and four focal lesions of the five cases in the pancreatic body (80%) were observable, whereas two lesions (adenocarcinoma in the pancreatic body, and adenoma in the uncus of pancreas) were not observable.
  • Ten cases with sessile type or semipedunculated type were diagnosed as adenoma or hyperplasia.
  • CONCLUSIONS: When combined with a videoscope and NBI, pancreatoscopy provided a clear image and was useful for evaluating whether the IPMN was benign or malignant.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Endoscopes. Endoscopy, Digestive System / instrumentation. Pancreatic Ducts. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Equipment Design. Female. Humans. Hyperplasia / diagnosis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447205.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


32. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F: Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol; 2008 Jan;129(1):81-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens.
  • Even though the cytologic criteria for pancreatic ductal adenocarcinoma (PDA) on fine-needle aspiration biopsy (FNAB) specimens have been well defined, a diagnostic challenge is still present.
  • We immunohistochemically evaluated the diagnostic value of S100P on cell-block and/or smear preparations in 58 cases of FNAB specimens of the pancreas.
  • The 58 cases were divided into 4 groups: 1, 32 cases of PDA; 2, 6 cases with an atypical or "suspicious" diagnosis; 3, 14 cases of benign or reactive ductal epithelium; and 4, 6 cases of endocrine tumor.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carrier Proteins / metabolism. Nuclear Proteins / metabolism. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / metabolism. Biopsy, Fine-Needle. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / metabolism. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089492.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / S100PBP protein, human
  •  go-up   go-down


33. Solís-López DR, Rodríguez-Hernández Z, Solís-López DH: Incidental adreno-cortical adenoma, why surgery? a case report. P R Health Sci J; 2010 Jun;29(2):130-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental adreno-cortical adenoma, why surgery? a case report.
  • INTRODUCTION: Incidental adrenal tumors are commonly benign, but reports demonstrate that if the characteristics of the tumor are not clear, on images surgery is the procedure of choice.
  • The pathological report was adrenal cortical adenoma with central hemorrhage and not a myelolipoma as described in images on magnetic resonance imaging (MRI).
  • CONCLUSION: The use of imaging for diagnosis, clinical management and decision making is very controversial.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Adenoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496530.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


34. Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S: 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg; 2007 Dec;246(6):932-7; discussion 937-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
  • OBJECTIVE: To assess the reliability of 18-fluorodeoxyglucose positron emission tomography (18-FDG PET) in distinguishing benign from malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and its contribution to surgical decision making.
  • SUMMARY BACKGROUND DATA: Pancreatic IPMNs are increasingly recognized, often as incidental findings, especially in people over age 70 and 80.
  • Computed tomography (CT) and magnetic resonance (MR) are unreliable in discriminating a benign from a malignant neoplasm.
  • 18-FDG PET as imaging procedure based on the increased glucose uptake by tumor cells has been suggested for diagnosis and staging of pancreatic cancer.
  • The validation of the diagnosis was made by a surgical procedure (n = 44), a percutaneous biopsy (n = 2), main duct cytology (n = 1), or follow-up (n = 17).
  • Forty-two patients underwent pancreatic resection, 2 palliative surgery, and 20 did not undergo surgery.
  • An adenoma was diagnosed in 13 patients, a borderline tumor in 8, a carcinoma in situ in 5, and an invasive cancer in 21; in 17 patients a tumor sampling was not performed and therefore the histology remained undetermined.
  • CONCLUSIONS: 18-FDG PET is more accurate than conventional imaging techniques (CT and MR) in distinguishing benign from malignant (invasive and noninvasive) IPMNs.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnosis. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043094.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Aparajita R, Gomez D, Verbeke CS, Menon KV: Papillary adenoma of the distal common bile duct associated with a synchronous carcinoma of the peri-ampullary duodenum. JOP; 2008;9(2):212-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma of the distal common bile duct associated with a synchronous carcinoma of the peri-ampullary duodenum.
  • CONTEXT: Benign tumours of the biliary tract are an extremely rare group of neoplasms.
  • The diagnosis of these rare tumours is established on histopathological analysis following resection.
  • Coincidence of a biliary adenoma of the distal common bile duct and a synchronous adenocarcinoma of the peri-ampullary duodenum has never been reported in the literature.
  • CASE REPORT: We report a case of a papillary adenoma in the common bile duct in a 75-year-old female, who had synchronous invasive adenocarcinoma of the peri-ampullary duodenum.
  • CONCLUSION: Isolated papillary adenoma of the bile duct is extremely rare, and in this unusual case it coincided with a peri-ampullary duodenal adenocarcinoma.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Common Bile Duct / pathology. Common Bile Duct Neoplasms / pathology. Duodenal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18326932.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


36. Yamaguchi H, Ishigami K, Inoue T, Eguchi T, Nagata S, Kuroda Y, Nishihara Y, Yamaguchi K, Tanaka M, Tsuneyoshi M: Three cases of serous oligocystic adenomas of the pancreas; evaluation of cyst wall thickness for preoperative differentiation from mucinous cystic neoplasms. J Gastrointest Cancer; 2007;38(1):52-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of serous oligocystic adenomas of the pancreas; evaluation of cyst wall thickness for preoperative differentiation from mucinous cystic neoplasms.
  • BACKGROUND: Serous oligocystic adenoma (SOA), a rare pancreatic neoplasm, is generally a benign lesion without the necessity of surgery.
  • The purpose of this study was to evaluate the cyst wall thickness of SOAs and MCNs for preoperative differential diagnosis.
  • The cyst wall thickness of the SOAs was evaluated in the area protruding out of the pancreas and was compared with that of 13 MCNs histopathologically.
  • [MeSH-major] Adenoma / pathology. Cysts / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Preoperative Care. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2005 Sep-Oct;30(5):610-5 [15759200.001]
  • [Cites] Pathology. 2002 Apr;34(2):148-56 [12009097.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Pathol Int. 2005 Jul;55(7):436-9 [15982220.001]
  • [Cites] Pancreas. 1998 Jan;16(1):40-4 [9436861.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jul;181(1):119-23 [12818841.001]
  • [Cites] Virchows Arch. 1994;424(1):13-7 [7526946.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Radiology. 2003 Sep;228(3):727-33 [12954892.001]
  • [Cites] Int J Pancreatol. 1993 Dec;14(3):283-9 [8113630.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(6):446-9 [14714166.001]
  • [Cites] Abdom Imaging. 1999 Jan-Feb;24(1):72-4 [9933678.001]
  • [Cites] J Clin Gastroenterol. 2005 Mar;39(3):253-6 [15718870.001]
  • [Cites] Int J Pancreatol. 2000 Aug;28(1):1-7 [11185705.001]
  • [Cites] Int J Pancreatol. 1991 Oct;10(2):161-72 [1748829.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1553-9 [16773248.001]
  • [Cites] J Gastroenterol. 2000;35(6):472-5 [10864357.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):467-70 [9931400.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Gastrointest Endosc. 2004 Jun;59(7):823-9 [15173795.001]
  • [Cites] Pancreas. 2005 Aug;31(2):182-7 [16025006.001]
  • [Cites] Cancer. 1992 May 15;69(10):2449-53 [1568167.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(1):92-6 [10982598.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2566-71 [12385440.001]
  • [Cites] Int J Pancreatol. 1996 Oct;20(2):135-9 [8968870.001]
  • [Cites] Hum Pathol. 1992 Aug;23(8):871-5 [1644432.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1401-5 [8898845.001]
  • [Cites] Pancreatology. 2003;3(6):482-6 [14673199.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • (PMID = 19065725.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Ishikawa T, Itoh A, Kawashima H, Ohno E, Matsubara H, Itoh Y, Nakamura Y, Nakamura M, Miyahara R, Hayashi K, Ishigami M, Katano Y, Ohmiya N, Goto H, Hirooka Y: Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc; 2010 May;71(6):951-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors.
  • BACKGROUND: Pancreatic endocrine tumors (PETs) develop in relatively few patients, but they are often difficult to diagnose because of their small size and various clinical symptoms.
  • OBJECTIVE: The aim of this study was to investigate the usefulness of EUS combined with contrast enhancement (CE-EUS) in the preoperative localization of PETs and the differentiation between malignant and benign PETs.
  • [MeSH-major] Pancreas / ultrasonography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Adenoma, Islet Cell / pathology. Adenoma, Islet Cell / ultrasonography. Adult. Aged. Carcinoma, Islet Cell / pathology. Carcinoma, Islet Cell / ultrasonography. Contrast Media. Diagnosis, Differential. Endosonography. Female. Humans. Male. Middle Aged. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / ultrasonography. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20438884.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


38. Yüksel M, Eziddin S, Wardelmann E, Biersack HJ: 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy. Rev Esp Med Nucl; 2006 Sep;25(5):316-9
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy.
  • A patient with suspicion of a neuroendocrine tumor of the pancreas underwent a somatostatin receptor scintigraphy using 111In-Pentetreotide.
  • 111In-pentetreotide scintigraphy showed discrete uptake of the radiotracer in the head of the pancreas and focal uptake in the right upper thyroid lobe.
  • Adding a 48h planar image might contribute to the differential diagnosis between benign or malignant lesions, as in the present case where the uptake decreased in an adenoma after 48 hours.
  • [MeSH-major] Adenoma / radionuclide imaging. Indium Radioisotopes / pharmacokinetics. Neuroendocrine Tumors / radionuclide imaging. Neuroendocrine Tumors / secondary. Positron-Emission Tomography. Radiopharmaceuticals / pharmacokinetics. Somatostatin / analogs & derivatives. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Chromogranin A / analysis. Diagnosis, Differential. False Positive Reactions. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Pancreatic Neoplasms / radionuclide imaging. Receptors, Somatostatin / metabolism. Serotonin / analysis. Thyroglobulin / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173778.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Indium Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 333DO1RDJY / Serotonin; 51110-01-1 / Somatostatin; 9010-34-8 / Thyroglobulin; G083B71P98 / pentetreotide
  •  go-up   go-down


39. Liang H, Wang XN, Wang BG, Pan Y, Ding XW, Hao XS: [Management of nonfunctioning islet cell tumors of the pancreas]. Zhonghua Zhong Liu Za Zhi; 2007 Jun;29(6):457-60
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of nonfunctioning islet cell tumors of the pancreas].
  • OBJECTIVE: To analyze the clinical and pathological features in order to investigate appropriate way of diagnosis and treatment for non-functional islet cell tumors of the pancreas (NFICT).
  • Twenty-eight patients were diagnosed as having non-functional islet cell carcinomas of the pancreas (NFICC) and 15 patients benign islet cell tumors.
  • Preoperatively, all of those were found to have a mass in their pancrease by ultrasonic and computed tomography examination, with 21 in the head, 10 in the body and 6 in the tail of the pancreas.
  • The resectability and curative resection rate in 28 patients with nonfunctioning islet cell carcinomas of the pancreas was 78.6% and 60.7%, respectively.
  • None of the 15 patients with benign nonfunctioning islet cell tumor of the pancreas died of this disease.
  • While the overall cumulative 5- and 10-year survival rate in 28 patients with non-functional islet cell carcinomas of the pancreas was only 58.1% and 29.0%, respectively.
  • CONCLUSION: Nonfunctioning islet cell tumor of the pancreas is frequently found in young female.
  • [MeSH-major] Adenoma, Islet Cell / therapy. Carcinoma, Islet Cell / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974283.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  •  go-up   go-down


40. Tanaka M, Kobayashi K, Mizumoto K, Yamaguchi K: Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol; 2005 Jul;40(7):669-75
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas.
  • Intraductal papillary mucinous neoplasm (IPMN) is a spectrum of neoplasia in the pancreatic duct epithelium characterized by cystic dilation of the main and/or branch pancreatic duct.
  • Most branch duct IPMNs are benign, whereas the other two types are often malignant.
  • A large size of branch duct IPMN and marked dilation of the main pancreatic duct indicate the presence of adenoma at least.
  • Of recent interest is the relatively high prevalence of synchronous and/or metachronous malignancy in various organs, including the pancreas.
  • The prognosis is favorable after complete resection of benign and noninvasive malignant IPMNs.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Pancreatectomy / methods. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 1987;2(6):727-30 [3438311.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Radiology. 1987 Oct;165(1):51-5 [3306789.001]
  • [Cites] Pancreas. 1991 Jan;6(1):15-22 [1994377.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(1):69-73 [10436239.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Hepatogastroenterology. 1995 Sep-Oct;42(5):730-3 [8751242.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):141-6 [8597507.001]
  • [Cites] Surgery. 1997 Sep;122(3):617-25 [9308621.001]
  • [Cites] Am J Surg. 1998 Mar;175(3):203-8 [9560120.001]
  • [Cites] Surgery. 2000 Nov;128(5):822-31 [11056446.001]
  • [Cites] Hepatogastroenterology. 1998 Mar-Apr;45(20):533-5 [9638444.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):512-9 [1648527.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1327-33 [1540869.001]
  • [Cites] Am J Surg Pathol. 1995 May;19(5):576-89 [7726368.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Am J Gastroenterol. 1991 Nov;86(11):1619-25 [1659183.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):722-7 [11375578.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):432-43; discussion 444-5 [2171441.001]
  • [Cites] Surgery. 1996 Nov;120(5):885-90 [8909526.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):454-61 [9028354.001]
  • [Cites] Gastroenterology. 1977 Dec;73(6):1410-2 [913983.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(5):466-72 [11180872.001]
  • [Cites] Am J Gastroenterol. 1991 Jul;86(7):835-9 [2058624.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Int J Pancreatol. 1997 Dec;22(3):227-31 [9444555.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Pancreatology. 2002;2(5):484-90 [12378117.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1986 Dec;83(12):2588-97 [3550180.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):159-68 [2049738.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):147-55 [14505148.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Gastrointest Endosc. 2003 Feb;57(2):205-9 [12556785.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Surgery. 2001 Jan;129(1):55-65 [11150034.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):692-709 [8799417.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):651-6 [1309676.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • (PMID = 16082582.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 58
  •  go-up   go-down


41. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • METHODS: Thirty-seven patients with IPMN of the pancreas, confirmed by surgical resection and typical findings of endoscopic ultrasonography and CT imaging between October 1, 1998 and August 31, 2006 were included.
  • Five, six, and two extrapancreatic malignancies had been diagnosed before, during, and after the diagnosis of IPMN.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


42. Schulz HU, Kellner U, Kahl S, Effenberger O, Asperger W, Lippert H, Röcken C: A giant pancreatic serous microcystic adenoma with 20 years follow-up. Langenbecks Arch Surg; 2007 Mar;392(2):209-13
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for microcystic adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A giant pancreatic serous microcystic adenoma with 20 years follow-up.
  • BACKGROUND AND AIMS: There is only little information about the spontaneous course of large pancreatic serous tumours.
  • We followed up a white woman with a giant serous microcystic adenoma over more than 20 years.
  • Finally, the initial biopsy specimen was re-evaluated, using immunohistochemistry, and the final diagnosis of a serous microcystic adenoma was made.
  • CONCLUSION: This unique case demonstrates that the spontaneous course of serous microcystic adenoma of the pancreas may be favourable even with huge tumour size and that immunohistochemistry may prove a valuable tool for differential diagnosis of cystic pancreatic lesions.
  • Due to their size and progressive, space-occupying growth, these biologically benign tumours may cause injury to adjacent organs and thus clinical symptoms.
  • [MeSH-major] Cystadenoma, Serous / surgery. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Chir Belg. 1992 Jan-Feb;92 (1):52-4 [1553850.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1086-94 [14614047.001]
  • [Cites] Int J Pancreatol. 1992 Apr;11(2):97-104 [1607732.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1963-6 [9772066.001]
  • [Cites] Am Surg. 2000 May;66(5):495-501 [10824753.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):269-74 [10587182.001]
  • [Cites] Pancreas. 1998 Jan;16(1):40-4 [9436861.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):497-509 [11459267.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Int J Pancreatol. 1993 Dec;14(3):283-9 [8113630.001]
  • [Cites] Langenbecks Arch Surg. 1998 Mar;383(1):56-61 [9627172.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Int J Pancreatol. 1991 Oct;10(2):161-72 [1748829.001]
  • [Cites] Ann Surg. 2004 May;239(5):651-7; discussion 657-9 [15082969.001]
  • [Cites] Int J Pancreatol. 1998 Apr;23(2):165-9 [9629514.001]
  • [Cites] Mol Cancer. 2003 Jan 07;2:7 [12537585.001]
  • [Cites] Oncol Rep. 2001 Jul-Aug;8(4):811-3 [11410789.001]
  • [Cites] Gastroenterol Clin Biol. 1995 Oct;19(10 ):848-9 [8566570.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Pancreas. 2003 Jan;26(1):42-8 [12499916.001]
  • [Cites] Praxis (Bern 1994). 1995 Feb 21;84(8):213-5 [7886358.001]
  • [Cites] Am J Pathol. 1997 Oct;151(4):951-6 [9327728.001]
  • [Cites] Chirurg. 1994 Jan;65(1):68-71 [8149804.001]
  • [Cites] Zentralbl Chir. 1997;122(2):122-5 [9173756.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):317-21 [11141506.001]
  • [Cites] Int J Pancreatol. 1996 Oct;20(2):135-9 [8968870.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Pancreatology. 2001;1(6):648-55 [12120249.001]
  • (PMID = 17235583.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


43. Itoh T, Hirooka Y, Itoh A, Hashimoto S, Kawashima H, Hara K, Kanamori A, Ohmiya N, Niwa Y, Goto H: Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol; 2005 Jan;100(1):144-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas.
  • BACKGROUND: The differentiation of benign from malignant intraductal papillary mucinous tumors (IPMT) is often difficult even by various examination methods.
  • We evaluated the qualitative and quantitative diagnostic ability of contrast-enhanced transabdominal ultrasonography (CE-US), mainly in differentiating benign from malignant tumors in patients with IPMT.
  • Pathological findings were 4 with carcinoma and 17 with adenoma.
  • In both the early and late phases, the post-enhancement intensity, difference between pre- and post-enhancement intensity, and the percentage change ((post-enhancement value-pre-enhancement value)/pre-enhancement value) were compared between malignant and benign lesions, and the ability of CE-US to differentiate between benign and malignant lesions was evaluated in comparison with the ability of EUS to diagnose the degree of malignancy. RESULTS:.
  • When the patients with carcinoma were compared with those with adenoma, the post-enhancement intensity was significantly higher, and the difference between pre- and post-enhancement intensity and the percentage change in the early phase and the late phase was significantly more marked in the carcinoma group (p= 0.019, p= 0.002, p= 0.015, p= 0.012, and p= 0.039, respectively).
  • Moreover, quantitative changes in intensity can be a parameter for the differential diagnosis of benign and malignant tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / ultrasonography. Adenocarcinoma, Papillary / ultrasonography. Carcinoma, Pancreatic Ductal / ultrasonography. Contrast Media. Pancreatic Neoplasms / ultrasonography. Polysaccharides

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654794.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Polysaccharides; 127279-08-7 / SHU 508
  •  go-up   go-down


44. Sugiyama M, Suzuki Y, Abe N, Mori T, Atomi Y: Management of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol; 2008;43(3):181-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intraductal papillary mucinous neoplasm of the pancreas.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a distinct entity characterized by papillary proliferations of mucin-producing epithelial cells with excessive mucus production and cystic dilatation of the pancreatic ducts.
  • IPMNs have malignant potential and exhibit a broad histologic spectrum, ranging from adenoma to invasive carcinoma.
  • The postoperative 5-year survival rate is nearly 100% for benign tumors and noninvasive carcinoma, and approximately 60% for invasive carcinoma.
  • Surgical treatment is indicated for a branch duct IPMN with suspected malignancy (tumor diameter > or = 30 mm, mural nodules, dilated main pancreatic duct, or positive cytology) or positive symptoms.
  • IPMNs are associated with a high incidence of extrapancreatic malignancies and pancreatic ductal carcinoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Aged. Female. Humans. Lymph Node Excision. Male. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):441-5 [10685747.001]
  • [Cites] Surgery. 2000 May;127(5):536-44 [10819062.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2001-8 [9951854.001]
  • [Cites] Surgery. 1997 Sep;122(3):617-25 [9308621.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1403-8 [10789803.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):164-71 [9717782.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1166-9 [12045867.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] World J Surg. 1998 Aug;22(8):874-8 [9673562.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):16-30 [10721804.001]
  • [Cites] Am J Gastroenterol. 1998 Feb;93(2):156-9 [9468232.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):460-8 [16616351.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1759-64 [17686073.001]
  • [Cites] Radiology. 2000 Dec;217(3):757-64 [11110940.001]
  • [Cites] Pancreatology. 2002;2(5):484-90 [12378117.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Am J Gastroenterol. 1993 Apr;88(4):564-9 [8385881.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Am J Surg. 2003 Mar;185(3):251-5 [12620565.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] J Gastroenterol. 2002;37(10):868-73 [12424574.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • (PMID = 18373159.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 37
  •  go-up   go-down


45. Yamaguchi T, Baba T, Ishihara T, Kobayashi A, Nakamura K, Tadenuma H, Ito H, Miyazaki M, Saisho H: Long-term follow-up of intraductal papillary mucinous neoplasm of the pancreas with ultrasonography. Clin Gastroenterol Hepatol; 2005 Nov;3(11):1136-43
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of intraductal papillary mucinous neoplasm of the pancreas with ultrasonography.
  • BACKGROUND & AIMS: Most intraductal papillary mucinous neoplasms of the pancreas (IPMNs) have a favorable prognosis.
  • METHODS: Eighty-one patients with IPMN were periodically subjected to US (>3 years); 27 were reviewed retrospectively (12 with benign neoplasms [adenoma, borderline] and 15 with malignant tumors [carcinoma in situ, invasive cancer]) and 54 prospectively.
  • US examination was focused on the main pancreatic duct (MPD) diameter, cyst diameter, and presence or absence and height of the protruding lesion.
  • Differences between the benign and malignant groups were examined to set the criteria for surgical treatment.
  • The majority of the prospective patients showed no significant changes of these parameters; however, 2 patients (3.7%) were operated on, with the post-surgery histopathologic diagnosis of cancer.
  • [MeSH-major] Carcinoma, Papillary / ultrasonography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Pancreatic Ductal / ultrasonography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pancreatic Ducts / ultrasonography. Prospective Studies. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271346.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Sidden CR, Mortele KJ: Cystic tumors of the pancreas: ultrasound, computed tomography, and magnetic resonance imaging features. Semin Ultrasound CT MR; 2007 Oct;28(5):339-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic tumors of the pancreas: ultrasound, computed tomography, and magnetic resonance imaging features.
  • Cystic tumors of the pancreas are a subset of rare pancreatic tumors that vary from benign to malignant.
  • This article aims to review the histopathologic and imaging findings of the relatively common lesions (serous microcystic adenoma, mucinous cystic tumor, intraductal papillary mucinous tumor, and solid pseudopapillary tumor) and uncommon lesions (cystic endocrine tumors, cystic metastases, cystic teratomas, and lymphangiomas) in this group.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Contrast Media. Cystadenocarcinoma / diagnosis. Cystadenocarcinoma / pathology. Cystadenoma / diagnosis. Cystadenoma / pathology. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970551.001).
  • [ISSN] 0887-2171
  • [Journal-full-title] Seminars in ultrasound, CT, and MR
  • [ISO-abbreviation] Semin. Ultrasound CT MR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 43
  •  go-up   go-down


47. Hayashibe A, Sakamoto K, Shinbo M, Makimoto S, Nakamoto T: A resected case of multiple intraductal papillary mucinous tumors of the pancreas with US-guided ductal branch-oriented partial pancreatectomy. Pancreatology; 2005;5(4-5):462-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A resected case of multiple intraductal papillary mucinous tumors of the pancreas with US-guided ductal branch-oriented partial pancreatectomy.
  • The cystic tumor of pancreas head had a diameter of 2 cm, and the mural nodule of the cystic tumor measured only 3 mm.
  • In the pancreas body the cystic tumor was measured at 1.5 cm with the mural nodule of the cystic tumor measuring 3 mm.
  • It was believed that the tumors were benign.
  • The reduction operation for preservation of pancreatic parenchyma should be selected for these circumstances.
  • Ductal branch-oriented partial pancreatectomy was performed on September 6, 2002 with intraoperative ultrasonography and a Cavitron Ultrasonic Aspirator, preserving the main pancreatic duct and normal pancreatic parenchyma.
  • The operation was successful, and the histopathological diagnosis of the tumors was intraductal papillary adenoma of the pancreas.
  • [MeSH-major] Adenoma / surgery. Digestive System Surgical Procedures. Pancreatectomy / methods. Pancreatic Ducts / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15985773.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


48. Noone TC, Hosey J, Firat Z, Semelka RC: Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab; 2005 Jun;19(2):195-211
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging and localization of islet-cell tumours of the pancreas on CT and MRI.
  • Islet-cell tumours are neuroendocrine tumours that arise from the endocrine pancreas.
  • They range from benign to malignant.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Gastrinoma / diagnosis. Humans. Insulinoma / diagnosis. Islets of Langerhans / pathology. Multiple Endocrine Neoplasia Type 1 / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763695.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 19
  •  go-up   go-down


49. Manfredi R, Graziani R, Motton M, Mantovani W, Baltieri S, Tognolini A, Crippa S, Capelli P, Salvia R, Pozzi Mucelli R: Main pancreatic duct intraductal papillary mucinous neoplasms: accuracy of MR imaging in differentiation between benign and malignant tumors compared with histopathologic analysis. Radiology; 2009 Oct;253(1):106-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Main pancreatic duct intraductal papillary mucinous neoplasms: accuracy of MR imaging in differentiation between benign and malignant tumors compared with histopathologic analysis.
  • PURPOSE: To retrospectively determine the accuracy of magnetic resonance (MR) imaging combined with MR cholangiopancreatography (CP) in differentiating benign from malignant intraductal papillary mucinous neoplasms (IPMNs) involving the main pancreatic duct (MPD), with histopathologic analysis as the reference standard.
  • Qualitative image analysis included assessment of the site of MPD dilatation (head of the pancreas, body and/or tail of the pancreas, or diffuse), presence or absence of duct wall nodules, and contrast enhancement of the MPD walls.
  • MPD wall nodules were observed in 16 carcinomas involving the MPD and one adenoma or borderline neoplasm (P < .00001).
  • The median maximal diameter of the MPD was 18 mm in malignant MPD or mixed type IPMNs and 11 mm in benign borderline IPMNs (P = .038).
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Cholangiopancreatography, Magnetic Resonance. Magnetic Resonance Imaging / methods. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Contrast Media. Diagnosis, Differential. Female. Ferrosoferric Oxide. Humans. Image Interpretation, Computer-Assisted. Logistic Models. Magnetite Nanoparticles. Male. Middle Aged. Retrospective Studies. Siloxanes. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703865.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / Siloxanes; 0 / ferumoxsil; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


50. Nanashima A, Takeshita H, Tobinaga S, Araki M, Sumida Y, Kunizaki M, Tanaka K, Abo T, Hidaka S, Sawai T, Yasutake T, Nagayasu T: Measurement of serum marker for bone metastasis (1-CTP) in hepatobiliary and pancreas malignancies. Hepatogastroenterology; 2010 Jul-Aug;57(101):694-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of serum marker for bone metastasis (1-CTP) in hepatobiliary and pancreas malignancies.
  • To clarify the significance of 1CTP in hepato-biliary pancreas malignancies, we examined the relationship between clinicopathological features and serum level of 1CTP.
  • METHODOLOGY: The subjects were 75 patients who underwent surgical resections including 27 patients with liver carcinomas, 15 with extra-hepatic biliary carcinomas, 14 pancreatic carcinomas and 19 benign diseases.
  • RESULTS: 1CTP level tended to be higher in the malignant diseases than in benign diseases but this difference was not significant (p = 0.065).
  • Compared to benign adenoma, 1CTP level in the malignant diseases was significantly higher (p = 0.049).
  • 1CTP level tended to be higher in patients with cholangitis compared to those with no inflammation or benign tumors (p = 0.065).
  • CONCLUSIONS: Serum level of 1CTP might be a predictive marker for hepatobiliary pancreas malignancies but also reflects the degree of co-existing cholangitis.
  • [MeSH-major] Biliary Tract Neoplasms / pathology. Biomarkers / blood. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Collagen Type I / blood. Liver Neoplasms / pathology. Pancreatic Neoplasms / pathology. Peptides / blood

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21033212.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Peptides; 0 / collagen type I trimeric cross-linked peptide
  •  go-up   go-down


51. Handra-Luca A, Fléjou JF, Rufat P, Corcos O, Belghiti J, Ruszniewski P, Degott C, Bedossa P, Couvelard A: Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma. Histopathology; 2006 Jun;48(7):813-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma.
  • AIMS: To examine cytokeratin, epithelial glycoprotein (mucin) and glycoprotein CD10 expression in benign mucinous cystdenomas (MCAs) in comparison with intraductal papillary mucinous adenomas (IPMAs).
  • METHODS AND RESULTS: Thirty MCAs of the pancreas were analysed for immunohistochemical expression of cytokeratin (CK) 7, CK20, MUC1, MUC2, MUC5AC and CD10 and were compared with 16 IPMAs.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / pathology. Cystadenoma, Mucinous / pathology. Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-20. Keratins / analysis. Male. Middle Aged. Mucin 5AC. Mucins / analysis. Neprilysin / analysis

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722930.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


52. Fujii T, Ishikawa T, Kanazumi N, Sugimoto H, Nomoto S, Inoue S, Nagasaka T, Takeda S, Nakao A: Analysis of clinicopathological features and predictors of malignancy in intraductal papillary mucinous neoplasms of the pancreas. Hepatogastroenterology; 2007 Jan-Feb;54(73):272-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of clinicopathological features and predictors of malignancy in intraductal papillary mucinous neoplasms of the pancreas.
  • RESULTS: The histological diagnosis was adenoma in 40, borderline in 1, carcinoma in situ (CIS) in 7, and invasive carcinoma in 9 patients.
  • Patients with invasive carcinomas had significantly shorter survival rates than patients with benign IPMNs or CIS (p < 0.0001).
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419275.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Number-of-references] 32
  •  go-up   go-down


53. Jang JY, Kim SW, Ahn YJ, Yoon YS, Choi MG, Lee KU, Han JK, Kim WH, Lee YJ, Kim SC, Han DJ, Kim YI, Choi SH, Cho BH, Yu HC, Yoon DS, Lee WJ, Lee KB, Kim YC, Lee KS, Kim MW, Kim HJ, Kim HJ, Park YH: Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol; 2005 Feb;12(2):124-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery?
  • BACKGROUND: Despite recently increasing numbers of reports on intraductal papillary mucinous tumors (IPMTs), difficulties still remain in terms of diagnosis, treatment, and prognosis.
  • A total of 124 patients underwent pancreatoduodenectomy, 42 underwent distal pancreatectomy, 17 underwent total pancreatectomy, and 25 underwent limited pancreatic resection.
  • There were 128 benign cases (adenoma, n = 62; borderline, n = 66) and 80 malignant cases (noninvasive, n = 29; invasive, n = 51).
  • A significant difference in 5-year survival was observed between the benign and malignant groups (92.6% vs. 65.3%; P = .006).
  • Of the six factors (age, location, duct dilatation, mural nodule, main duct type, and tumor size) that showed statistical differences by univariate analysis between the benign and malignant groups, three were significant by multivariate analysis--namely, mural nodule (P = .009), tumor size (P = .023), and a dilated duct size (P = .010).
  • CONCLUSIONS: A significant proportion of IPMTs are malignant, although the overall prognosis of IPMT is superior to that of ordinary pancreatic cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):98-9 [15827786.001]
  • (PMID = 15827792.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


54. Hirano S, Kondo S, Tanaka E, Shichinohe T, Suzuki O, Shimizu M, Itoh T: Role of CT in detecting malignancy during follow-up of patients with branch-type IPMN of the pancreas. Hepatogastroenterology; 2009 Mar-Apr;56(90):515-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of CT in detecting malignancy during follow-up of patients with branch-type IPMN of the pancreas.
  • BACKGROUND/AIMS: This retrospective study evaluated the suitability of computed tomography (CT) to detect malignancy while following patients with branch-type IPMN, most of which are benign and may be treated with observation alone.
  • METHODOLOGY: Forty-two surgical specimens resected from patients with a diagnosis of branch-type IPMN were pathologically classified as benign (n=26), which included hyperplasia and adenoma, or malignant (n=16), including moderate dysplasia or adenocarcinoma.
  • It was compared the differences in the sizes of the tumor and main pancreatic duct (MPD) and the presence of mural nodules on CT between the groups.
  • RESULTS: In the malignant group, it was observed a larger tumor size (47.8 vs. 23.8 mm; p = 0.001) and increased dilation of the MPD (9.3 vs. 5.0 mm; p = 0.001) than those seen in the benign group.
  • The accuracy of CT diagnosis of mural nodules, however, was only 62%.
  • Increases in these morphological characteristics on CT images during the follow-up period would be an accurate method to predict a diagnosis of malignancy.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Papillary / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579633.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


55. Basturk O, Coban I, Adsay NV: Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med; 2009 Mar;133(3):423-38
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications.
  • CONTEXT: Cystic lesions of the pancreas are being recognized with increasing frequency and have become a more common finding in clinical practice because of the widespread use of advanced imaging modalities and the sharp drop in the mortality rate of pancreatic surgery.
  • Consequently, in the past 2 decades, the nature of many cystic tumors in this organ has been better characterized, and significant developments have taken place in the classification and in our understanding of pancreatic cystic lesions.
  • OBJECTIVE: To provide an overview of the current concepts in classification, differential diagnosis, and clinical/biologic behavior of pancreatic cystic tumors.
  • CONCLUSIONS: In contrast to solid tumors, most of which are invasive ductal adenocarcinomas with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • However, those that are mucinous, namely, intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, constitute an important category because they have well-established malignant potential, representing an adenoma-carcinoma sequence.
  • Those that are nonmucinous such as serous tumors, congenital cysts, lymphoepithelial cysts, and squamoid cyst of pancreatic ducts have no malignant potential.
  • Only rare nonmucinous cystic tumors that occur as a result of degenerative/necrotic changes in otherwise solid neoplasia, such as cystic ductal adenocarcinomas, cystic pancreatic endocrine neoplasia, and solid-pseudopapillary neoplasm, are also malignant and have variable degrees of aggressiveness.
  • [MeSH-major] Pancreatic Cyst / diagnosis. Pancreatic Cyst / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology. Pancreatic Pseudocyst / diagnosis. Pancreatic Pseudocyst / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260748.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 204
  •  go-up   go-down


56. Linder JD, Geenen JE, Catalano MF: Cyst fluid analysis obtained by EUS-guided FNA in the evaluation of discrete cystic neoplasms of the pancreas: a prospective single-center experience. Gastrointest Endosc; 2006 Nov;64(5):697-702
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyst fluid analysis obtained by EUS-guided FNA in the evaluation of discrete cystic neoplasms of the pancreas: a prospective single-center experience.
  • BACKGROUND: Accurate assessment of pancreatic cystic neoplasms is imperative before selecting available treatment options, such as surgical resection, drainage, or conservative therapy.
  • Available modalities, CT and magnetic resonance imaging, have been inconsistent in diagnosis.
  • Reports involving EUS and cyst fluid analysis have been encouraging, including studies of EUS features and/or cyst fluid analysis, which may differentiate pancreatic cystic neoplasms.
  • SETTING: Pancreatic Biliary Center, St Luke's Medical Center, Milwaukee, Wisconsin.
  • PATIENTS: A total of 102 patients (60 women, 42 men; age, 23-76 years) presented for evaluation of pancreatic cystic neoplasm; 71 underwent surgical resection.
  • The CEA level was significantly higher in MCyA (adenoma [878 ng/mL], carcinoma [27,581 ng/mL]) vs PC (189 ng/mL), and SCyA (121 ng/mL).
  • CONCLUSIONS: Differential diagnosis of pancreatic cystic neoplasm is significantly enhanced by cyst fluid analysis.
  • Malignant from benign MCN can be differentiated by CEA levels > or =6000 ng/mL.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle / methods. Cyst Fluid / chemistry. Endosonography. Pancreatic Neoplasms / chemistry. Pancreatic Pseudocyst / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2006 Nov;64(5):703-4 [17055860.001]
  • (PMID = 17055859.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Mucins; EC 3.1.1.3 / Lipase; EC 3.2.1.- / Amylases
  •  go-up   go-down


57. Gonzalvez Gasch AM, Mirete Ferrer C, Laveda Cano R, Satorres Rosas J: A case of a solid renal mass together with a cystic pancreatic lesion in a 50-year-old patient. JOP; 2005 Mar;6(2):172-7
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a solid renal mass together with a cystic pancreatic lesion in a 50-year-old patient.
  • CONTEXT: Pancreatic cysts may be incidentally detected in asymptomatic patients evaluated for other clinical manifestations.
  • Microcystic adenomas are particularly rare among pancreatic cyst neoplasms.
  • They are benign lesions and can present as solitary pancreatic tumors or as a radiological manifestation combined with other cystic and tumoral lesions affecting different organs.
  • A computed tomography scan of the abdomen showed a 9-centimeter renal mass in the left kidney consistent with a renal-cell carcinoma as well as a cystic lesion the head of the pancreas.
  • The histopathological study of the cystic mass, following a computed tomography guided biopsy, showed a microcystic adenoma.
  • Therefore, further studies were performed so as to assess the relationship between both lesions and determine the final diagnosis.
  • CONCLUSIONS: Microcystic adenomas are exceedingly rare tumors among pancreatic cysts.
  • The combination of a solid renal mass and a pancreatic cystic lesion should lead to a broad differential diagnosis.
  • Pancreatic magnetic resonance imaging has been proven to be particularly useful in evaluating cystic masses.
  • The presence of walls and internal septations in the pancreatic mass with gadolinium enhancement should raise the possibility of an underlying Von Hippel-Lindau syndrome.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis. von Hippel-Lindau Disease / diagnosis
  • [MeSH-minor] Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / pathology. Diagnosis, Differential. Hemangioblastoma / complications. Hemangioblastoma / diagnosis. Hemangioblastoma / pathology. Hematuria / diagnosis. Hematuria / etiology. Hematuria / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767734.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


58. Hornick JL, Lauwers GY, Odze RD: Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol; 2005 Mar;29(3):381-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
  • Not uncommonly, bile duct adenomas (BDAs) and hamartomas (BDHs) of the liver may be difficult to distinguish from metastatic well-differentiated ductal adenocarcinoma of the pancreas.
  • The primary purpose of this study was to determine if a panel of immunohistochemical stains can help distinguish BDA or BDH from metastatic pancreatic adenocarcinoma in the liver.
  • Routinely processed tissue sections from 25 BDA, 10 BDH, 25 metastatic pancreatic adenocarcinomas to the liver and 6 cases each of metastatic colorectal, breast, and lung adenocarcinomas were immunohistochemically stained for CK7, CK8/CK18, CK19, CK20, p53, p63, TAG-72, monoclonal CEA (mCEA), polyclonal CEA (pCEA), HER-2/neu, AMACR (alpha-methylacyl-CoA racemase), Dpc4 (Smad4), and mesothelin.
  • The slides were evaluated in a blinded fashion, and the results were compared between the benign and malignant lesions.
  • Significantly more (P < 0.05) metastatic pancreatic adenocarcinomas were positive for CK20 (76%), p53 (60%), TAG-72 (88%), mCEA (92%), HER2/neu (40%), and mesothelin (64%) and showed loss of Dpc4 (44%), in comparison to BDA (CK20, 40%; p53, 0%; TAG-72, 0%; mCEA, 0%; HER2/neu, 12%; mesothelin, 0%; loss of Dpc4, 0%) or BDH (CK20, 10%; p53, 0%; TAG-72, 0%; mCEA, 10%; HER2/neu, 0%; mesothelin, 0%; loss of Dpc4, 0%).
  • Of these antibodies, p53, TAG-72, mCEA, loss of Dpc4, and mesothelin had the highest specificity for pancreatic adenocarcinoma, with mCEA having the highest sensitivity (92%).
  • Although none of the BDA or BDH was positive for either p63 or AMACR, two of the metastatic pancreatic adenocarcinomas (8%) were positive for each of these peptides (P > 0.05).
  • For nonpancreatic adenocarcinomas, mCEA showed a reasonably high sensitivity and 100% specificity in the differential diagnosis versus BDA.
  • Immunohistochemical expression of p53, TAG-72, mCEA, mesothelin, and loss of Dpc4 can help distinguish metastatic pancreatic adenocarcinoma in the liver from BDA or BDH.
  • Although p63 and AMACR are also specific for pancreatic adenocarcinoma, their low sensitivity limits their use in clinical practice.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Bile Duct Neoplasms / pathology. Hamartoma / pathology. Liver Diseases / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques


59. Ridolfini MP, Gourgiotis S, Alfieri S, Di Miceli D, Rotondi F, Limongelli F, Quero G, Larghi A, Cazzato MT, Martella N, Doglietto GB: [Presentation, treatment and prognosis of intraductal papillary mucinous neoplasm]. Ann Ital Chir; 2007 Jul-Aug;78(4):257-64
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms (IPMNs) are rare tumours rising from the pancreatic duct epithelium.
  • They are characterized by intraductal papillary growth and thick mucin secretion; mucin fills the Wirsung and/or branch pancreatic ducts and may cause ductal dilatation.
  • Most branch type IPMNs are benign, while the other two types are frequently malignant.
  • Recent advances in diagnostic imaging have led to an increased frequency of diagnosis of IPMNs, but the clinical features of them can range broadly from benign, borderline, and malignant non-invasive to invasive lesions, and their management has not yet been clearly defined.
  • Presence of a large branch type IPMN and marked dilatation of the main duct indicate the existence of adenoma.
  • Endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasonography (EUS), intraductal ultrasonography, and magnetic resonance cholangiopancreatography (MRCP) are the most valuable imaging techniques for diagnosis of these lesions.
  • Prognosis is excellent after complete resection of benign and non-invasive malignant IPMNs.
  • Total pancreatectomy should be reserved for patients with resectable but extensive IPMN involving the whole pancreas; its benefits must be balanced against perioperative risks.
  • [MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Pancreatic Ductal. Pancreatic Neoplasms
  • [MeSH-minor] Aged. Diagnosis, Differential. Dilatation, Pathologic / etiology. Female. Humans. Male. Middle Aged. Pancreatic Ducts. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990599.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 75
  •  go-up   go-down


60. Krzysztof K, Wiktor B, Tadeusz Ł, Waldemar B, Magdalena K, Janusz D: Neuroendocrine tumours--analysis of own material--a nine--year retrospective study. Hepatogastroenterology; 2010 Mar-Apr;57(98):236-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In the present study were observed 6 cases of carcinoids localized in ileum, cecum and sigmoid colon, 1 case of gastrinoma in pancreatic head localization, 1 case of insulinoma localized in pancreatic tail, 1 case of vipoma localised in pancreatic head, 2 cases of nesidioblastoma and 1 case of microcystic adenoma with neuroendocrine differentiation in pancreatic tail localization and 1 case of nonspecific apudoma observed in ileum.
  • There were 6 cases of neuroendocrine tumours localized in pancreas.
  • In adrenal glands we observed 10 benign and 1 malignant pheochromocytoma (one bilateral female case with Multiple Endocrine Neoplasia type 2A).
  • The clinical manifestations of some neuroendocrine tumours are not specific, so it causes a lot of difficulties in early diagnosis and treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583420.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


61. Krysiak R, Okopień B, Herman ZS: [Insulinoma]. Pol Merkur Lekarski; 2007 Jan;22(127):70-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulinoma is considered the most common endocrine tumour of the pancreas with an annual prevalence of 4 cases per million people.
  • Contrary to the other endocrine tumours of this organ, over 90% of the insulinomas are benign in nature.
  • Effective management requires directed biochemical testing, careful choice of preoperative imaging tests, and complete pancreatic exploration by an experienced endocrine surgeon utilising intraoperative ultrasound.
  • The aim of this paper is to critically discuss contemporary diagnosis and treatment of this neoplasm on the basis of progress made in recent years.
  • [MeSH-major] Adenoma, Islet Cell / complications. Adenoma, Islet Cell / diagnosis. Insulinoma / complications. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endocrine Surgical Procedures / methods. Gastrinoma / complications. Gastrinoma / diagnosis. Gastrinoma / metabolism. Gastrinoma / surgery. Humans. Hypoglycemia / complications. Insulin / metabolism. Pancreatectomy / methods. Prognosis. Rare Diseases

  • Genetic Alliance. consumer health - Insulinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17477096.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Insulin
  • [Number-of-references] 34
  •  go-up   go-down


62. Singh A, Pandey KC, Pant NK: Cavitary mucoepidermoid carcinoma of lung with metastases in skeletal muscles as presenting features: a case report and review of the literature. J Cancer Res Ther; 2010 Jul-Sep;6(3):350-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Later studies showed that they can arise as a primary in bronchus, esophagus, lacrimal glands, pancreas, thymus and thyroid gland.
  • Initially described as a benign adenoma, it is now considered to be a malignant epithelial tumor.
  • [MeSH-major] Carcinoma, Mucoepidermoid / diagnosis. Lung Neoplasms / diagnosis. Muscle Neoplasms / secondary. Muscle, Skeletal / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119274.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


63. Paik WH, Yoon YB, Lee SH, Park JK, Woo SM, Yang KY, Seo JK, Ryu JK, Kim YT: [Pancreatic endocrine tumors: clinical manifestations and predictive factors associated with survival]. Korean J Gastroenterol; 2008 Sep;52(3):171-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic endocrine tumors: clinical manifestations and predictive factors associated with survival].
  • BACKGROUND/AIMS: Since pancreatic endocrine tumors (PET) are rare and heterogeneous diseases, their survival and prognosis are not well known.
  • Due to recent advances in CT/MRI technology, incidentalomas of the pancreas are detected with increasing frequency.
  • Overall 5-year survival rate was 68.1%, and 5-year survival rate of the patients who had distant metastases at initial diagnosis was 43.9%.
  • CONCLUSIONS: Because small and pathologically benign nature do not predict good prognosis in PET, aggressive treatment such as curative resection would be considered initially even in the case of incidental PET.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / mortality. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lymph Nodes / pathology. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077513.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


64. Ikenaga N, Yamaguchi K, Konomi H, Fujii K, Sugitani A, Tanaka M: A minute nonfunctioning islet cell tumor demonstrating malignant features. J Hepatobiliary Pancreat Surg; 2005;12(1):84-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ultrasonography and computed tomography demonstrated a well-defined pancreatic tumor, 8 mm in diameter, in the body of the pancreas.
  • Serum levels of pancreatic hormones were within normal limits, and thus a tentative diagnosis was nonfunctioning islet cell tumor.
  • The resected specimen showed an endocrine tumor invading both the pancreatic parenchyma and the perineural spaces outside the tumor.
  • In general, minute nonfunctioning islet cell tumors have been considered to be completely benign, but the present tumor showed clear malignant features.
  • [MeSH-major] Adenoma, Islet Cell / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Diagnostic Imaging. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754106.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Goh BK, Tan YM, Yap WM, Cheow PC, Chow PK, Chung YF, Wong WK, Ooi LL: Pancreatic serous oligocystic adenomas: clinicopathologic features and a comparison with serous microcystic adenomas and mucinous cystic neoplasms. World J Surg; 2006 Aug;30(8):1553-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic serous oligocystic adenomas: clinicopathologic features and a comparison with serous microcystic adenomas and mucinous cystic neoplasms.
  • INTRODUCTION: The preoperative distinction between serous cystic neoplasms (SCNs) and mucinous cystic neoplasms (MCNs) is essential, as all MCNs are considered malignant or potentially malignant and should be surgically resected, whereas SCNs are almost always benign.
  • However, the radiologic distinction between SCNs and MCNs is frequently difficult especially with serous oligocystic adenoma (SOA), a morphologic variant of SCN, as both SOA and MCN appear on cross-sectional imaging as a solitary macrocystic lesion in the pancreas.
  • We reviewed all SOAs managed at our institution to determine if any clinicopathologic features would prove useful for establishing a preoperative diagnosis.
  • METHODS: Over a 15-year period, 64 patients with a pathologically confirmed diagnosis of a pancreatic cystadenoma or cystadenocarcinoma treated at Singapore General Hospital were retrospectively reviewed.
  • Most of the cysts were located in the body or tail of the pancreas (9/12), and the median cyst size was 52.5 mm (range 10-190 mm).
  • However, SOAs occurred in the women less frequently (67.3% vs. 96.3%, P=0.004), were smaller [40 mm (range 10-190 mm) vs. 95 mm (range 25-180 mm), P<0.001], and occurred more commonly in the head of the pancreas [25 (48.1%) vs. 2(7.4%)] compared to MCNs.
  • On the other hand, SOAs differ from MCNs by their relatively higher male/female ratio, higher frequency of tumors occurring in the head of the pancreas, and smaller cyst size.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Serous / diagnosis. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2002 Apr;34(2):148-56 [12009097.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):497-509 [11459267.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jul;181(1):119-23 [12818841.001]
  • [Cites] Virchows Arch. 1994;424(1):13-7 [7526946.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Radiology. 2003 Sep;228(3):727-33 [12954892.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1330-6 [15131794.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Abdom Imaging. 1999 Jan-Feb;24(1):72-4 [9933678.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1529 [15887144.001]
  • [Cites] Int J Pancreatol. 2000 Aug;28(1):1-7 [11185705.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):132-9 [1546898.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1026-31 [15551256.001]
  • [Cites] J Comput Assist Tomogr. 1997 May-Jun;21(3):373-82 [9135643.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):282-7 [15780564.001]
  • [Cites] Gastrointest Endosc. 2005 Mar;61(3):363-70 [15758904.001]
  • [Cites] J Gastroenterol. 2000;35(6):472-5 [10864357.001]
  • [Cites] Aust N Z J Surg. 1998 Dec;68(12 ):844-6 [9885865.001]
  • [Cites] Gastrointest Endosc. 2004 Jun;59(7):823-9 [15173795.001]
  • [Cites] Pancreatology. 2001;1(6):641-7 [12120248.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2566-71 [12385440.001]
  • [Cites] Dig Dis Sci. 2005 Nov;50(11):2170-7 [16240235.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Hum Pathol. 1992 Aug;23(8):871-5 [1644432.001]
  • [Cites] Pancreatology. 2003;3(6):482-6 [14673199.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • (PMID = 16773248.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Cheng CL, Fogel EL, Sherman S, McHenry L, Watkins JL, Croffie JM, Gupta SK, Fitzgerald JF, Lazzell-Pannell L, Schmidt S, Lehman GA: Diagnostic and therapeutic endoscopic retrograde cholangiopancreatography in children: a large series report. J Pediatr Gastroenterol Nutr; 2005 Oct;41(4):445-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications included biliary pathology (n = 93), pancreatic pathology (n = 111), and chronic abdominal pain of suspected biliary or pancreatic origin (n = 41).
  • The ERCP findings were bile duct stone(s) (n = 29), benign biliary stricture (n = 19), primary sclerosing cholangitis (n = 7), anomalous pancreaticobiliary union (n = 8), choledochal cyst (n = 5), bile duct leak (n = 6), malignant biliary stricture (n = 2), biliary atresia (n = 1), chronic pancreatitis (n = 44), pancreas divisum (n = 26), pancreatic duct stricture with (n = 6) or without (n = 9) leak, pancreatic tumor (n = 1), periampullary adenoma (n = 2), and sphincter of Oddi dysfunction (n = 65).
  • [MeSH-major] Biliary Tract Diseases / diagnosis. Biliary Tract Diseases / therapy. Cholangiopancreatography, Endoscopic Retrograde. Pancreatic Diseases / diagnosis. Pancreatic Diseases / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205513.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Colagrande S, Carbone SF, Carusi LM, Cova M, Villari N: Magnetic resonance diffusion-weighted imaging: extraneurological applications. Radiol Med; 2006 Apr;111(3):392-419
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With regard to the latter, although there are differences between benign forms [focal nodular hyperplasia (FNH), adenoma] and malignant forms [metastasis, hepatocellular carcinoma (HCC)] in their apparent diffusion coefficient (ADC) in the average values for histological type, there is a significant overlap in values when lesions are assessed individually, with the consequent problem of their correct identification.
  • Here it is possible to differentiate mucin-producing tumours of the pancreas from pseudocystic forms on the basis of ADC values even though the limited spatial resolution of Dw imaging does not enable the identification of small lesions.
  • [MeSH-minor] Bone Diseases / diagnosis. Echo-Planar Imaging. Humans. Kidney Diseases / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis. Pancreatic Diseases / diagnosis. Soft Tissue Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683086.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 63
  •  go-up   go-down


68. Schick V, Franzius C, Beyna T, Oei ML, Schnekenburger J, Weckesser M, Domschke W, Schober O, Heindel W, Pohle T, Juergens KU: Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging; 2008 Oct;35(10):1775-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound.
  • PURPOSE: This prospective single-centre phase II trial assessed the diagnostic impact of (18)F-FDG PET-CT in the evaluation of solid pancreatic lesions (phi >or= 10 mm) compared to endosonography (EUS), endoscopic retrograde cholangio-pancreatography (ERCP) with intraductal ultrasound (IDUS), abdominal ultrasound (US) and histopathological reference.
  • METHODS: Forty-six patients (32 men/14 women, phi 61.7 years) with suspected pancreatic neoplasms underwent PET-CT with contrast-enhanced biphasic multi-detector CT of the upper abdomen followed by a diagnostic work-up with EUS, ERCP with IDUS and US within 3 weeks.
  • RESULTS: Twenty-seven pancreatic malignancies were histopathologically proven; 19 patients had benign diseases: 36/46 lesions (78%) were detected in the head of the pancreas, 7/46 and 3/46 in the body and tail region, respectively.
  • PET analysis revealed significantly higher maximum mean standardised uptake values (SUV(max) 6.5+/-4.6) in patients with pancreatic malignancy (benign lesions: SUV(max) 4.2+/-1.5; p<0.05).
  • PET-CT revealed cervical lymphonodal metastasis from occult bronchogenic carcinoma and a tubular colon adenoma with intermediate dysplasia on polypectomy, respectively.
  • CONCLUSIONS: (18)F-FDG PET-CT achieves a comparably high diagnostic impact evaluating small solid pancreatic lesions versus conventional reference imaging modalities.
  • [MeSH-major] Cholangiopancreatography, Endoscopic Retrograde. Endoscopy, Digestive System. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods. Ultrasonography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2006 Nov-Dec;40(10 ):923-9 [17063113.001]
  • [Cites] J Gastrointest Surg. 2005 Jan;9(1):22-8; discussion 28-9 [15623441.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Aug;132(33):1696-700 [17713866.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10 ):753-63 [15545675.001]
  • [Cites] J Clin Ultrasound. 1986 Jun;14(5):339-53 [3088049.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):527-31 [17960376.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1134-9 [11571948.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):700-8 [15855975.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):194-9 [10100786.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1565-70 [9843289.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1386-91 [12094855.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):367-71 [10968852.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):722-7 [11375578.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jul 1;24(1):87-94 [16803606.001]
  • [Cites] Ann Intern Med. 2001 Mar 20;134(6):459-64 [11255521.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Ann Surg. 1999 May;229(5):729-37; discussion 737-8 [10235532.001]
  • [Cites] Surg Endosc. 2005 Mar;19(3):369-73 [15624058.001]
  • [Cites] Endoscopy. 2006 Dec;38(12):1246-9 [17163327.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1684-9 [15330902.001]
  • [Cites] JOP. 2003 Jan;4(1):68-74 [12555018.001]
  • [Cites] JOP. 2004 Jul;5(4):289-303 [15254364.001]
  • [Cites] Rofo. 2007 Jul;179(7):693-702 [17592808.001]
  • [Cites] Eur J Nucl Med. 1997 Jun;24(6):678-82 [9169578.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):252-61 [15017610.001]
  • [Cites] Oncology (Williston Park). 2002 Jan;16(1):29-38, 43; discussion 44, 47-9, 53-6 [11831609.001]
  • [Cites] Radiology. 1991 Feb;178(2):328-30 [1987587.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(1):4-10 [15747028.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):475-80 [12540455.001]
  • [Cites] Radiographics. 2005 Nov-Dec;25(6):1451-68; discussion 1468-70 [16284127.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3662-6 [17659723.001]
  • [Cites] Med Phys. 1998 Oct;25(10 ):2046-53 [9800714.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Dig Surg. 2005;22(1-2):55-61; discussion 62 [15838173.001]
  • [Cites] Rofo. 2007 Jan;179(1):72-9 [17146750.001]
  • [Cites] Semin Nucl Med. 2006 Jul;36(3):248-56 [16762614.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):280-8 [15019924.001]
  • [Cites] Chang Gung Med J. 2005 May;28(5):274-83 [16086542.001]
  • [Cites] Cancer. 2000 Dec 15;89(12 ):2547-54 [11135214.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Pancreas. 2005 Aug;31(2):192-4 [16025008.001]
  • [Cites] Ann Nucl Med. 2003 Jul;17 (5):421-6 [12971645.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1279-86 [15299049.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] J Nucl Med. 2002 Feb;43(2):173-80 [11850481.001]
  • [Cites] Scand J Gastroenterol. 2002 Nov;37(11):1313-20 [12465731.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1121-9 [11036292.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2006 Oct;33(3):211-20 [17003640.001]
  • [Cites] Pancreatology. 2005;5(4-5):398-402 [15985763.001]
  • (PMID = 18481063.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down






Advertisement